 |
 |
NCCN指南已經(jīng)將CPT-11聯(lián)合鉑類列為晚期非小細(xì)胞肺癌一線治療方案。本項(xiàng)研究結(jié)果顯示，CPT-11+DDP治療晚期NSCLC療效確切，用藥劑量患者尚可耐受，對于CPT-11所導(dǎo)致的骨髓抑制及腹瀉反應(yīng)及早進(jìn)行干預(yù)，但對于晚期復(fù)治及多程治療后患者及KPS評分<70分患者，如何使用CPT-11值得進(jìn)一步深入研究。
【參考文獻(xiàn)】
[1] 程剛.晚期非小細(xì)胞肺癌的研究進(jìn)展[M]∥馬軍，秦叔逵.中國臨床腫瘤學(xué)教育專輯.北京:中國協(xié)和醫(yī)科大學(xué)出版社，2009：14-18.
[2] Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study [J]. J Clin Oncol，1997，15(1):297-303.
[3] Comer AM, Goa KL. Docetaxel: a review of its use in non-small cell lung cancer [J]. Drugs Aging，2000，17(1):53-80.
[4] Gebbia V, Caruso M, Valenza R, et al. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma [J]. Anticancer Res，1994，14(3B):1247-1249.
[5] 楊學(xué)寧，吳一龍.實(shí)體瘤治療療效評價(jià)標(biāo)準(zhǔn)-RECIST[J].循證醫(yī)學(xué),2004,4(2):85-90;111.
[6] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med，2002，346(2):92-98醫(yī).學(xué)全.在.線網(wǎng)站quanxiangyun.cn.
[7] Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer [J]. J Clin Oncol，1994，12(1):90-96.
[8] DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer [J]. J Clin Oncol， 1999，17(9):2710-2720.
[9] Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan [J]. Ann Oncol，2007，18(2):317-323.
